|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.320 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion</b>: Has-miR-222-3p and target genes<i>,</i> especially <i>CBFB</i>, <i>UBE2N</i>, may serve as prognostic predictors for HCC.
|
31258758 |
2019 |
|
Hypertensive disease
|
0.010 |
AlteredExpression
|
group |
BEFREE |
<b>Results:</b> Comparative with control group, in hypertension associated with hyperlipidemia the investigated miRNA expression profiles were different: (i) in plasma, the levels of all investigated miRNAs were significantly increased, the highest enhances being noticed for miR-21,-146a,-221,-143,-34a, and miR-204; (ii) in platelets, the expressions of almost all miRNAs were significantly elevated, remarkable for miR-126,-146a,-223,-222, and miR-214, while levels of miR-143, miR-10a, and miR-145 were significantly reduced; (iii) in PMVs, numerous miRNAs were found to have significantly increased levels, especially miR-222,-221,-210, and miR-34a, whereas expressions of various miRNAs as miR-223,-214,-146a,-143,-10a, and miR-145 were significantly decreased.
|
31850358 |
2019 |
|
Hyperlipidemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>Results:</b> Comparative with control group, in hypertension associated with hyperlipidemia the investigated miRNA expression profiles were different: (i) in plasma, the levels of all investigated miRNAs were significantly increased, the highest enhances being noticed for miR-21,-146a,-221,-143,-34a, and miR-204; (ii) in platelets, the expressions of almost all miRNAs were significantly elevated, remarkable for miR-126,-146a,-223,-222, and miR-214, while levels of miR-143, miR-10a, and miR-145 were significantly reduced; (iii) in PMVs, numerous miRNAs were found to have significantly increased levels, especially miR-222,-221,-210, and miR-34a, whereas expressions of various miRNAs as miR-223,-214,-146a,-143,-10a, and miR-145 were significantly decreased.
|
31850358 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
<i>Conclusion:</i> A panel of miRNAs with miR-146a, miR-222 and miR-223 could be used as potential noninvasive biomarkers for early detection of AD.
|
28123597 |
2017 |
|
Hurthle Cell Tumor
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<i>In situ</i> hybridization showed a nuclear staining pattern. miR-126, miR-222 and miR-200b were significantly differentially expressed between the subtypes by <i>in situ</i> hybridization. miRNA expression could distinguish RCC subtypes and oncocytoma. miRNA expression assessed by either PCR or <i>in situ</i> hybridization can be a clinically useful diagnostic tool to complement morphologic renal tumor classification, improving diagnosis and patient management.
|
29416756 |
2018 |
|
Oncocytic Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<i>In situ</i> hybridization showed a nuclear staining pattern. miR-126, miR-222 and miR-200b were significantly differentially expressed between the subtypes by <i>in situ</i> hybridization. miRNA expression could distinguish RCC subtypes and oncocytoma. miRNA expression assessed by either PCR or <i>in situ</i> hybridization can be a clinically useful diagnostic tool to complement morphologic renal tumor classification, improving diagnosis and patient management.
|
29416756 |
2018 |
|
Oxyphilic Adenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<i>In situ</i> hybridization showed a nuclear staining pattern. miR-126, miR-222 and miR-200b were significantly differentially expressed between the subtypes by <i>in situ</i> hybridization. miRNA expression could distinguish RCC subtypes and oncocytoma. miRNA expression assessed by either PCR or <i>in situ</i> hybridization can be a clinically useful diagnostic tool to complement morphologic renal tumor classification, improving diagnosis and patient management.
|
29416756 |
2018 |
|
Gastrointestinal Stromal Tumors
|
0.030 |
GeneticVariation
|
group |
BEFREE |
<i>KIT</i> 3'UTR rs17084733 and pri-miR-222 rs75246947 were found significantly associated with GIST susceptibility.
|
30983504 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor miRNA expression by RT-qPCR correlated with tumor grade, size, and presence of carcinoma in situ for miR-222, recurrence (miR-222 and miR-143), progression (miR-222 and miR-143), disease-specific survival (miR-222), and overall survival (miR-222).
|
22426337 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer.
|
22854542 |
2012 |
|
Colorectal Carcinoma
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
CRC cell lines (HCT116 and RKO) were transfected with miR-221 or miR-222 mimics or inhibitors.
|
24931456 |
2014 |
|
Infection caused by Helicobacter pylori
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
H. pylori infection leads to significantly higher miR-221 and miR-222 expression.
|
26364844 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor xenografts were then used to investigate the role of miR-222-3p in OS growth in vivo.
|
30584323 |
2018 |
|
Squamous cell carcinoma of tongue
|
0.020 |
Biomarker
|
disease |
BEFREE |
MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines.
|
19487542 |
2009 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
|
23994196 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
|
23994196 |
2013 |
|
recurrent papillary thyroid cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.
|
24301304 |
2013 |
|
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MicroRNA-222 and miR-146b were over-expressed 10.8-fold and 8.9-fold, respectively, in Rc-PTC tumors compared with NR-PTC tumors (P = .014 and P = .038, respectively).
|
24301304 |
2013 |